US Patent 11,103,477 (Drug): What the Claims Cover and How the Patent Landscape Tightens Around Them
What does US 11,103,477 claim?
US Patent 11,103,477 is drafted narrowly around a specific patient profile, a specific risk endpoint, and a specific dosing of a specific omega-3 ethyl ester.
Core independent claim (Claim 1)
Claim 1 is a method claim:
- Population: a subject on statin therapy with atrial fibrillation or atrial flutter and elevated triglyceride levels
- Purpose: reducing risk of myocardial infarction
- Intervention: administering about 4 g of ethyl eicosapentaenoate per day
Stated as coverage logic, the claim requires all of the following to be present:
1) statin use
2) atrial fibrillation or atrial flutter
3) elevated triglycerides
4) myocardial infarction (MI) risk reduction
5) dosing at “about 4 g/day” of ethyl eicosapentaenoate
Dependent claims add three layers of specificity
The dependent claims lock down:
- Baseline LDL-C window (Claim 2): about 40 to 100 mg/dL
- Composition purity and omega-3 dominance (Claim 3): ethyl eicosapentaenoate is in a pharmaceutical composition and at least about 96 wt% of all omega-3 fatty acids in the composition
- Capsule fill format (Claim 4): about 1 g per capsule in 4 capsules
- Triglyceride thresholds and ranges (Claims 5-7):
- at least about 300 mg/dL (Claim 5)
- at least about 500 mg/dL (Claim 6)
- about 500 mg/dL to about 1500 mg/dL (Claim 7)
Claim architecture summary table
| Claim |
What it narrows |
Threshold / parameter |
| 1 |
Patient + endpoint + dose |
Statin + AF/atrial flutter + elevated TG; reduce MI risk; administer about 4 g/day ethyl eicosapentaenoate |
| 2 |
Adds lipid context |
LDL-C about 40-100 mg/dL |
| 3 |
Adds composition spec |
Ethyl eicosapentaenoate composition where ethyl eicosapentaenoate is ≥96 wt% of omega-3 fatty acids |
| 4 |
Adds dosage form math |
4 capsules with about 1 g each |
| 5 |
Adds TG floor |
TG ≥300 mg/dL |
| 6 |
Adds TG floor |
TG ≥500 mg/dL |
| 7 |
Adds TG range |
TG 500-1500 mg/dL |
What is the likely claim construction risk for competitors?
This patent is vulnerable to “design-around” only in a limited set of ways because the claim is a tight combination claim. The main risk drivers are the elements that are hard to vary:
1) Dosing is explicit
Claim 1 requires about 4 g/day of ethyl eicosapentaenoate. Competitors who materially under-dose (for example, 2 g/day or 1 g/day) reduce the likelihood of infringement on Claim 1, but may fail the medical-effect positioning that underpins the regulatory strategy.
2) The endpoint is specific: myocardial infarction risk reduction
The claim does not say “reduce cardiovascular events” broadly. It states “reducing risk of myocardial infarction.” That language forces the method claim to tie the prescribed regimen to MI risk reduction.
3) The population is restrictive: AF/atrial flutter + statin + elevated TG
This is a narrower cohort than general hypertriglyceridemia or general secondary prevention. The combination makes “label-mismatch” an infringement risk even if triglycerides are treated.
4) Composition specs can matter even in method cases
Claim 3 includes a compositional requirement: the ethyl eicosapentaenoate in the composition accounts for at least about 96 wt% of omega-3 fatty acids. That can matter for any generic or reformulated omega-3 ethyl ester product where the omega-3 profile differs (for example, different ratios of eicosapentaenoic vs docosahexaenoic fractions).
5) Capsule dosing format is an additional constraint
Claim 4 is a dosage-form constraint: about 1 g per capsule in 4 capsules to approximate 4 g/day. If a competitor uses different capsule amounts or different unit dose counts, the claim 4 element is not met. But Claim 1 is still the main risk if dose and population elements match.
What does the claim set imply about the product being targeted?
Even without identifying the brand name, the claim reads like an omega-3 ethyl ester at a high dose consistent with a “4 g/day ethyl eicosapentaenoate” regimen. The specific technical hook is:
- “ethyl eicosapentaenoate” (EPA ethyl ester)
- “about 4 g per day”
- composition where it is “at least about 96 wt%” of omega-3 fatty acids
- dosing could align with 4 x 1 g capsules
The claims do not cover:
- mixed omega-3 free fatty acids rather than ethyl esters
- non-EPA omega-3 dominant products where EPA is not ≥96 wt% of omega-3 fatty acids
- regimens not used in statin-treated subjects
- endpoints not framed as MI risk reduction
- triglyceride profiles outside the stated thresholds if a dependent claim is asserted
How does the dependent claim range strategy shape enforcement?
Claims 5-7 build an escalation ladder for triglyceride criteria:
- a moderate threshold (≥300 mg/dL)
- a higher threshold (≥500 mg/dL)
- a numeric range (500-1500 mg/dL)
This structure helps the patentee capture different segments of clinical practice and different clinical trial inclusion criteria. It also supports multiple infringement theories:
- If a competitor’s protocol targets TG ≥500 mg/dL, Claims 6 and 7 align
- If it targets TG ≥300 mg/dL, Claim 5 aligns
- If it targets a narrower TG range, Claim 7 offers the most specific tether
Where does the landscape likely cluster around this patent?
The enforceable “center of gravity” is a method using:
- EPA ethyl ester at ~4 g/day
- in AF/atrial flutter patients on statins
- with elevated triglycerides
- aiming at MI risk reduction
- optionally pinned by LDL-C 40-100 mg/dL
- and composition purity (≥96 wt% omega-3 fraction)
- and a 4-capsule unit dose format
In a typical omega-3 patent landscape, competing technical routes tend to fall into four buckets:
1) Different EPA dose levels (below ~4 g/day)
2) Different omega-3 chemical forms (non-ethyl ester vs ethyl ester)
3) Different formulation/omega-3 composition ratios (EPA not at ≥96 wt% of omega-3 fatty acids)
4) Different patient selection or endpoints (no AF/atrial flutter, no statin background, or endpoint not MI risk reduction)
What “design-around” options are most visible from these claims?
From the claim text alone, the cleanest separation is to avoid at least one required element in Claim 1. The most direct separations are:
- Not giving ~4 g/day EPA ethyl ester
- Not targeting patients with AF or atrial flutter
- Not restricting to statin-treated subjects
- Not framing the method objective as MI risk reduction
- Not using a regimen for “elevated triglycerides” as understood in the claim (since dependent claims pin thresholds, a competitor could target lower TG)
Partial separations may still leave infringement exposure on Claim 1:
- If a competitor matches AF/atrial flutter + statin + elevated TG and uses ~4 g/day EPA ethyl ester but uses different capsule unit sizes, Claim 4 may not be met, but Claim 1 can still be met.
For Claim 3 and Claim 4 specifically:
- If a competitor uses a composition where EPA is not ≥96 wt% of omega-3 fatty acids, Claim 3 fails.
- If a competitor uses a different capsule scheme than 4 x 1 g, Claim 4 fails.
How broad is the protection in practice?
Protection breadth depends on the claim element that is easiest for a competitor to change:
- Broad element: “about 4 g/day” gives some flexibility (“about”), but it still anchors dosing tightly around 4 g/day.
- Narrow element: AF/atrial flutter + statin-treated + elevated TG narrows to a specific clinical combination.
- Enforcement leverage: dependent claims offer additional “fallback” criteria (LDL-C band, TG thresholds, composition purity, capsule math), which can be used depending on the competitor’s real-world protocol.
What should business teams infer from this claim set for freedom-to-operate?
1) Label strategy is not the only risk vector
Even if a product label is broader or different in wording, infringement of method claims can still turn on actual patient selection and dosing practices. The claim requires a method tied to the risk reduction in MI.
2) Clinical protocol details matter as much as chemistry
Trial inclusion criteria (AF/atrial flutter, statin background, triglyceride thresholds) and dosing arms (exact EPA ethyl ester dose) are the main levers.
3) Formulation purity can be a defensible differentiator
The ≥96 wt% omega-3 fatty acids composition requirement in Claim 3 makes formulation composition a potential design-around point, not just dose selection.
Key Takeaways
- US 11,103,477 is a method-of-treatment patent centered on ~4 g/day ethyl eicosapentaenoate to reduce myocardial infarction risk in statin-treated patients with atrial fibrillation or atrial flutter and elevated triglycerides.
- Dependent claims add enforceable constraints for LDL-C (40-100 mg/dL), composition purity (≥96 wt% omega-3 fatty acids are ethyl eicosapentaenoate), capsule math (4 capsules of ~1 g each), and triglyceride criteria (≥300, ≥500, or 500-1500 mg/dL).
- The most visible design-around is to change at least one required element of Claim 1, especially dose, AF/atrial flutter population, statin background, or the MI risk reduction framing.
- Formulation composition and unit-dose scheme are additional, narrower levers for avoiding dependent claims, even if Claim 1 remains the core risk.
FAQs
1) Does this patent cover EPA in any form?
The claim explicitly requires ethyl eicosapentaenoate. Coverage is tied to that chemical form.
2) Is the triglyceride requirement optional?
No. Elevated triglycerides are part of Claim 1, and dependent claims further quantify thresholds and ranges.
3) What is the exact daily dose claimed?
Claim 1 requires about 4 g per day of ethyl eicosapentaenoate.
4) Do the capsule claims control the whole patent?
No. Capsule constraints appear in dependent Claim 4. Claim 1 can still be implicated even if unit dose formats differ, provided the other required elements are met.
5) What are the main “escape routes” for competitors?
Most direct escape routes are changing one or more of: ~4 g/day dosing, AF/atrial flutter population, statin background, or the method endpoint (MI risk reduction). Secondary routes include avoiding the ≥96 wt% omega-3 purity and the 4 x 1 g capsule scheme.
References
[1] United States Patent 11,103,477, claims 1-7 (provided in prompt text).
